Newsletter October 2020: ESAIC contributes to a public-private partnership that tackles major challenges in the care of pain patients

To improve the care of patients with acute or chronic pain, a consortium from academia, small and medium-sized enterprises (SMEs), pain societies, patient organisations and the pharmaceutical industry has launched the research project “IMI-Pain Care – Improving the care of patients suffering from acute or chronic pain”.

IMI-PainCare is set within the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership for health research worldwide. A consortium of 40 partners from 14 countries is running the project, ESA being one of them. IMI-PainCare is supported by the IMI 2 Joint Undertaking. The project runs over four years and includes 3 subprojects: BioPain, TriPP and PROMPT.

The consortium strives to develop a toolbox that can streamline the research and development process for novel analgesic drugs and improve treatment quality in clinical practice. The project comprises three sub-projects across all phases of the pharmaceutical value chain – from early research to clinical practice – addressing major challenges in the care of patients suffering from acute or chronic pain in a complementary manner. It is anticipated that tools will be validated that will allow patient stratification.

ESAIC is mainly involved in the PROMPT subproject. PROMPT aims at reaching an international consensus on pain-related patient-reported outcomes that will be used both in clinical routine as well as in randomised controlled trials (RCTs). This will lead to better comparability of studies, improved design of analgesic trials reflecting the needs of patients, and translation of research into clinical practice. Therefore, this project is of high importance for anaesthesiologists who work at the forefront of acute and chronic pain management. ESA’s main tasks will be the dissemination of project results.


Please visit our website for more information on the IMI-PainCare project! www.imi-paincare.eu


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777500. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. www.imi.europa.eu


This communication reflects the views of the IMI-PainCare consortium and neither IMI nor the European Union and EFPIA is liable for any use that may be made of the information contained herein.


More Newsletter Articles

Visit our Euroanaesthesia 2020 Website for more news on everything related to the virtual congress.

Visit our COVID-19 Resource Hub for other news and resources.

Leave a Reply

Your email address will not be published. Required fields are marked *